Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: TruFin hails "strong" trading; SkinBio falls

14th Aug 2025 11:16

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday.

----------

AIM - WINNERS

----------

TruFin PLC, up 18% at 117.88 pence, 12-month range 42.00p-118.44p. TruFin predicts sharp half-year revenue growth amid "momentum" at games publisher Playstack. The holding company of three growth-focused technology businesses operating in early payment provision, invoice finance and mobile games publishing, says revenue in the six months to June 30 rose 40% to GBP35.5 million from GBP25.3 million a year prior. "This strong performance has been primarily driven by continued momentum within Playstack," it adds. Adjusted earnings before interest, tax, depreciation and amortisation of GBP6.7 million are expected, more than doubling on-year from GBP2.9 million.

----------

OptiBiotix Health PLC, up 15% at 11.75p, 12-month range 10.00p-27.00p. The life sciences business says a product containing its Slimbiome appetite reducing offering has been launched. It has been launched in Hydroxycut, a weight loss supplement in the US. "This news is significant for the company as it represents the inclusion of SlimBiome in the products of one of the USA's most popular weight management brands which has led to orders totalling just under five metric tonnes for SlimBiome in 2025. The board believes that the opportunity has potential for future development and will provide further updates in due course," it adds.

----------

AIM - LOSERS

----------

SkinBioTherapeutics PLC, down 7.3% at 14.25p, 12-month range 9.00p-27.50p. The life science firm focused on skin health expects to report weaker annual revenue than market forecasts, due to order timing. It expects revenue for the year to June 30 between GBP4.5 million and GBP4.8 million, jumping from GBP1.2 million a year prior. "Revenues were slightly lower than market expectations due to timing of orders for Dermatonics and BTS, much of which occurred just after the year end," it adds.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to [email protected]

Copyright 2025 Alliance News Ltd. All Rights Reserved.


Related Shares:

OptiBiotix HealthTrufin PlcSkinbiotherap.
FTSE 100 Latest
Value9,201.22
Change23.98